{sup 99m}Tc radiopharmaceuticals for brain perfusion imaging
Conference
·
OSTI ID:139684
- Mallinckrodt Medical, Inc., St. Louis, MO (United States)
- Univ. of Missouri, Columbia (United States)
It is well established that small, neutral, lipophilic technetium complexes can diffuse into the brain and then be trapped intracellularly by a variety of mechanisms. A more detailed understanding of the structural and chemical parameters which promote efficient diffusion into the brain, and which underlie the trapping mechanisms, will be necessary to delineate the clinical relevance of current agents, and to design improved technetium 99 pharmaceuticals. Current technetium 99 brain-perfusion imaging agents do not show ideal characteristics of brain uptake and retention. Furthermore, significant fractions of the technetium 99 complexes are lost between site of injection and the brain. Thus, it is difficult to use these current agents to quantitate regional cerebral blood flow. Nevertheless, these agents are proving extremely valuable for the SPECT evaluation of abnormalities in brain perfusion patients with neurological disorders.
- Research Organization:
- Brookhaven National Lab., Upton, NY (United States)
- OSTI ID:
- 139684
- Report Number(s):
- CONF-9110368--; ON: TI92014827; CNN: Grant CA-42179
- Country of Publication:
- United States
- Language:
- English
Similar Records
Regional brain uptake and retention of Tc-99m-propylene amine oxime derivatives
Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease
New Tc-99m brain imaging agents
Conference
·
Wed May 01 00:00:00 EDT 1985
· J. Nucl. Med.; (United States)
·
OSTI ID:6760920
Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease
Journal Article
·
Thu Sep 01 00:00:00 EDT 1988
· J. Nucl. Med.; (United States)
·
OSTI ID:6746062
New Tc-99m brain imaging agents
Conference
·
Sat Dec 31 23:00:00 EST 1983
· J. Nucl. Med.; (United States)
·
OSTI ID:6575341